$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib 1 Â for the treatment of neuroblastoma, a type of cancer most commonly affecting babies...
RALEIGH, N.C. and TEL-AVIV, Israel , June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that...
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing...
RHB-204 1 Â is a next-generation optimized formulation of RedHill's oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking...
2025 was a year of tenacity, strategic transactions and building traction for RedHill
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential...
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and...
RHB-102 1 Â is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute...